Stifel analyst Daniel Arias raised the firm’s price target on Illumina (ILMN) to $155 from $135 and keeps a Buy rating on the shares. The firm thinks there is “a case to be made” for mid-single digit organic growth for this year under “a fairly defensible set of inputs,” the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina: Rich Valuation Amid Mounting Competitive and Execution Risks Supports Sell Rating
- Cathie Wood Doubles Down on High-Potential Biotech Plays
- Midday Fly By: JPMorgan reports mixed Q4, L3Harris to form new missile company
- Illumina introduces Billion Cell Atlas
- Illumina sees Q4 non-GAAP EPS $1.27-$1.30, consensus $1.21